阿糖胞苷
医学
米托蒽醌
内科学
依托泊苷
中性粒细胞减少症
移植
胃肠病学
人口
髓系白血病
外科
造血干细胞移植
白血病
肿瘤科
化疗
环境卫生
作者
Markus Andreas Schaich,Christoph Röllig,Silke Soucek,Michael Krämer,Christian Thiede,Brigitte Mohr,Uta Oelschlaegel,Norbert Schmitz,Reingard Stuhlmann,Hannes Wandt,Kerstin Schäfer‐Eckart,Walter E. Aulitzky,Martin Kaufmann,Heinrich Bodenstein,J. Tischler,Anthony Dick Ho,Alwin Krämer,Martin Bornhäuser,Johannes Schetelig,Gerhard Ehninger
标识
DOI:10.1200/jco.2010.33.7303
摘要
PURPOSE: To assess the optimal cumulative dose of cytarabine for treatment of young adults with acute myeloid leukemia (AML) within a prospective multicenter treatment trial. PATIENTS AND METHODS: Between 1996 and 2003, 933 patients (median age, 47 years; range 15 to 60 years) with untreated AML were randomly assigned at diagnosis to receive cytarabine within the first consolidation therapy at either a intermediate-dose of 12 g/m² (I-MAC) or a high-dose of 36 g/m² (H-MAC) combined with mitoxantrone. Autologous hematopoietic stem-cell transplantation or intermediate-dose cytarabine (10 g/m²) were offered as second consolidation. Patients with a matched donor could receive an allogeneic transplantation in a risk-adapted manner. RESULTS: After double induction therapy including intermediate-dose cytarabine (10 g/m²), mitoxantrone, etoposide, and amsacrine, complete remission was achieved in 66% of patients. In the primary efficacy analysis population, a consolidation with either I-MAC or H-MAC did not result in significant differences in the 5-year overall (30% v 33%; P = .77) or disease-free survival (37% v 38%; P = .86) according to the intention-to-treat analysis. Besides a prolongation of neutropenia and higher transfusion demands in the H-MAC arm, rates of serious adverse events were comparable in the two groups. CONCLUSION: In young adults with AML receiving intermediate-dose cytarabine induction, intensification of the cytarabine dose beyond 12 g/m² within first consolidation did not improve treatment outcome.
科研通智能强力驱动
Strongly Powered by AbleSci AI